Understanding the First JCAs: Practical Takeaways for Key Stakeholders

June 23, 2026

Back to all webinars

Title: Understanding the First JCAs: Practical Takeaways for Key Stakeholders

Tuesday, June 23, 2026
11:00AM EDT | 3:00PM UTC | 5:00PM CEST

Click here for time zone conversion

Registration Coming Soon!

Description

As the EU Joint Clinical Assessment (JCA) framework enters its first phase of real world implementation, pharmaceutical manufacturers are beginning to confront the practical implications for evidence generation, PICO development, and launch planning. With the first JCA reports emerging, this session will unpack how early experiences can inform near term decisions for market access strategy, evidence plans, and patient outcomes.

Designed specifically for pharmaceutical industry teams involved in evidence planning, market access, and launch preparedness, this webinar will translate high level policy concepts into concrete, actionable considerations for upcoming launches and lifecycle management.

A panel of seasoned experts will explore what has been most unexpected in early JCA assessments, how manufacturers are adapting their evidence packages in response, and how JCA outputs may potentially influence national level decision making processes—whether by HTA bodies, payers, or other authorities, depending on the market. Given the evolving nature of JCA implementation, the discussion will highlight areas of uncertainty while offering practical guidance for how companies can prepare now. 

Attendees will hear perspectives from industry market access leaders and patient representatives, leaving with a clear understanding of the emerging lessons from the first JCAs, a refined view of the risks and opportunities ahead, and a short list of actions pharma teams can take in the coming months to strengthen planning, align cross functional teams, and better anticipate downstream implications across Europe. Interactive polls and Q&A will ensure the session reflects real world challenges facing evidence and access leaders today.

 

Learning Objectives

  • Key learnings from the first year of JCA implementation.
  • Reflections on the implications for market access, regulatory processes, and patient involvement.
  • Initial reactions to the first JCA outputs, preparatory materials, and emerging assessment practices.
  • What’s next to better prepare for success?

Moderator:

Ruairi O’Donnell, PhD, Vice President, Market Access and Healthcare Consulting Europe, Cencora, Oxford, United Kingdom

Speakers:

Antonella Cardone, MBA, CEO, Cancer Patients Europe, San Miniato, Italy

Eelko den Breejen, MSc, Global Head, Global Access & Value, Pfizer, Amsterdam, the Netherlands

Neil Grubert, MA, Independent Global Market Access Consultant, London, United Kingdom


Sponsored by Corporate Partner, Cencora.


 

Please note: On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar. Reservations are on a first-come, first-served basis.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×